4Kemminer SE, Cortradt HS, Nimtz M, et aL Production and molecular characterization of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24. Biotechnol Prog,2001,17 :809-821.
5Kaufmann R, Spieth K, Leiter U, et al. Temozolom in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase, multicenter study from the dematologic cooperative oncology group. J Clin Oncol,2005,23 : 9001-9007.
6Weber RW, O'day S, Rose M, et al. Low-dose outpatient chemo biotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha 2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol,2005,23 : 31.
7Lawson DH. Choices in adjuvamal therapy of melanoma. Cancer Control ,2005,12:236-241.
8Tomita K, Nakamura E, Okabe S. Histamine regulates growth of malignant melanoma implants via H ( 2 ) receptors in mice. Inflammophamacology ,2005,13 : 282 -289.
9[4]Kemminer SE,Conradt HS,Nimtz M,et al.Production and molecular characterization of clinical phase Ⅰanti-melanoma mouse IgG3 monoclonal antibody R24[J].Biotechnol Prog,2001,17(5):809-821.
10[7]Kaufmann R,Spieth K,Leiter U,et al.Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma:A Randomized,Phase III,Multicenter Study from the Dermatologic Cooperative Oncology Group[J].J Clin Oncol,2005,23(35):9001-9007.
